EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients

Feifei Fan, Guozhong Jiang iD, Juan Lv, Hongmin Wang, Wenjie Li, Chenglin Liu, Yu Zhao, Zhou Zhang, Haiwei Du, Zhihong Zhang, Xiangnan Li, Wen-Cai Li iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70078 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Feifei Fan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Lung Neoplasms, High-Throughput Nucleotide Sequencing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for noninvasive cancer diagnostics, particularly in the context of metastatic non‐small‐cell lung cancer (NSCLC). Detecting targetable variants through ctDNA analysis offers the potential to guide treatment decisions, especially in cases where tissue samples are insufficient or unavailable.

Method

In this study, we developed and validated a next‐generation sequencing panel targeting 101 cancer‐related genes (101‐test) to detect somatic variants in ctDNA from a large cohort of Chinese patients with metastatic NSCLC. The performance of the 101‐test was assessed by evaluating its limit of detection (LOD), accuracy, and precision in identifying molecular variants. Additionally, the concordance between ctDNA and tissue samples for detecting targetable variants was analyzed in 904 patients.

Results

The 101‐test demonstrated a LOD of 0.38% for single‐nucleotide variants (SNVs), 0.33% for insertions and deletions (InDels), and 0.33% for fusions. Sensitivity was 98.3% for SNVs, 100% for InDels, and 100% for fusions when compared to digital droplet PCR (ddPCR)/breakpoint PCR reference methods. The by‐variant sensitivity for somatic variants was 97.5%, with a specificity of 99.9% between tumor‐only and tumor‐normal analyses. In a real‐world cohort, the concordance between ctDNA and tissue samples for identifying targetable variants was 72.2% (457/633). Notably, the EGFR S768I variant, recently recommended by clinical guidelines, achieved an 80% concordance rate. Furthermore, 4.3% of patients (27/633) with targetable variants were identified exclusively through ctDNA testing.

Conclusion

The ctDNA‐based 101‐test is a highly sensitive and specific tool for detecting targetable variants in metastatic NSCLC, particularly in cases with insufficient tissue samples. The findings support the use of ctDNA testing as a reliable and complementary method to traditional tissue‐based molecular analysis, enhancing the precision of treatment strategies for NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsHigh-Throughput Nucleotide SequencingBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedAdultAged, 80 and overPolymorphism, Single NucleotideLimit of DetectionSensitivity and SpecificityMutation

Stichwörter der Autor:innen

circulating tumor DNAconcordancenext‐generation sequencingtargetable variantstissue sample

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Respiratory Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Burning Rock Biotech, Guangzhou, China.
  • Department of Thoracic Surgery and Lung Transplantation, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Guozhong Jiang, Wen-Cai Li

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Fan, F., Jiang, G., Lv, J., Wang, H., Li, W., Liu, C., Zhao, Y., Zhang, Z., Du, H., Zhang, Z., Li, X., & Li, W. C. (2024). Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients. Cancer Medicine. https://doi.org/10.1002/cam4.70078

Vancouver

Fan F, Jiang G, Lv J, Wang H, Li W, Liu C, et al. Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients. Cancer Medicine. 2024. doi:10.1002/cam4.70078

BibTeX
@article{Fan2024,
  author = {Fan, Feifei and Jiang, Guozhong and Lv, Juan and Wang, Hongmin and Li, Wenjie and Liu, Chenglin and Zhao, Yu and Zhang, Zhou and Du, Haiwei and Zhang, Zhihong and Li, Xiangnan and Li, Wen-Cai},
  title = {Analytical and clinical validation of a NGS panel in detecting targetable variants from ctDNA of metastatic NSCLC patients},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70078}
}
Kostenlos starten →